Basic Information
| LncRNA/CircRNA Name | MIR22HG |
| Synonyms | NA |
| Region | GRCh38_17:1711493-1717174 |
| Ensemble | ENSG00000186594 |
| Refseq | NR_028502 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | chloride | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qRT-PCR, RNA-seq |
| Sample | HCC and paired non-cancer tissues |
| Expression Pattern | down-regulated |
| Function Description | MIR22HG was downregulated in HCC and that this downregulation correlated with the malignant phenotype of HCC.Co-expressed genes of MIR22HG, identified by weighted correlation network analysis (WGCNA), mainly participated in the pathways involving osteoclast differentiation, chemokine signaling pathways, and hematopoietic cell lineage. In vivo experiments demonstrated that nitidine chloride could stimulate MIR22HG expression in HCC xenografts. |
| Pubmed ID | 31819482 |
| Year | 2019 |
| Title | MIR22HG As A Tumor Suppressive lncRNA In HCC: A Comprehensive Analysis Integrating RT-qPCR, mRNA-Seq, And Microarrays |
External Links
| Links for MIR22HG | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |